U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C28H39N3O3
Molecular Weight 465.6276
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CID-2858522

SMILES

CC1=C(C)C=C2N(CC(=O)C3=CC(=C(O)C(=C3)C(C)(C)C)C(C)(C)C)C(NCCCO)=NC2=C1

InChI

InChIKey=CYCGGKILBWERDJ-UHFFFAOYSA-N
InChI=1S/C28H39N3O3/c1-17-12-22-23(13-18(17)2)31(26(30-22)29-10-9-11-32)16-24(33)19-14-20(27(3,4)5)25(34)21(15-19)28(6,7)8/h12-15,32,34H,9-11,16H2,1-8H3,(H,29,30)

HIDE SMILES / InChI

Molecular Formula C28H39N3O3
Molecular Weight 465.6276
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

CID-2858522 is the potent and selective inhibitor of protein kinase C (PKC)-induced activation of the NF-κB pathway (IC50 < 0.1 μM for PMA-stimulated IL-8 production). CID-2858522 inhibits antigen receptor-stimulated NF-κB activation in chronic lymphocytic leukemia (CLL) B cells. CID-2858522 does not inhibit other NF-κB pathways, including that activated by tumor necrosis factor (TNF).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.07 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway.
2010 Mar 1
Patents

Patents

Sample Use Guides

In vivo dose-exposure profiling of 1a was conducted using a small cohort of three male mice was subjected to single ip doses at 10, 30, and 50 mg/kg. Blood was drawn at 0.5 and 3 h, and subsequent LC/MS analysis.
Route of Administration: Intraperitoneal
PMA/Iono induced NF-kB luciferase assay was done in HEK293- NF-kB-Luc stable cells HEK293-NF-kB-Luc cells were seeded in 96-well white plates overnight. CID-2858522 was diluted in culture medium and 5 mkL was added to the cells to reach a final concentration 5mkM. 2 h later, 5 mkL PMA/Iono (200 ng/mL) was added (final concentration = 10 ng/mL) and cells were treated for another 16 h. 50 mkL. BriteLite solution (Perkin–Elmer) was added to each well and luminescence was read using a luminometor.
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:24:04 GMT 2023
Edited
by admin
on Sat Dec 16 18:24:04 GMT 2023
Record UNII
Z744D8S6JG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CID-2858522
Code English
1-(3,5-BIS(1,1-DIMETHYLETHYL)-4-HYDROXYPHENYL)-2-(2-((3-HYDROXYPROPYL)AMINO)-5,6-DIMETHYL-1H-BENZIMIDAZOL-1-YL)ETHANONE
Systematic Name English
1-(3,5-DI-TERT-BUTYL-4-HYDROXYPHENYL)-2-(2-(3-HYDROXYPROPYLAMINO)-5,6-DIMETHYL-1H-BENZO(D)IMIDAZOL-1-YL)ETHANONE
Systematic Name English
CID2858522
Common Name English
ETHANONE, 1-(3,5-BIS(1,1-DIMETHYLETHYL)-4-HYDROXYPHENYL)-2-(2-((3-HYDROXYPROPYL)AMINO)-5,6-DIMETHYL-1H-BENZIMIDAZOL-1-YL)-
Systematic Name English
Code System Code Type Description
FDA UNII
Z744D8S6JG
Created by admin on Sat Dec 16 18:24:04 GMT 2023 , Edited by admin on Sat Dec 16 18:24:04 GMT 2023
PRIMARY
CAS
758679-97-9
Created by admin on Sat Dec 16 18:24:04 GMT 2023 , Edited by admin on Sat Dec 16 18:24:04 GMT 2023
PRIMARY
PUBCHEM
2858523
Created by admin on Sat Dec 16 18:24:04 GMT 2023 , Edited by admin on Sat Dec 16 18:24:04 GMT 2023
PRIMARY
EPA CompTox
DTXSID30386304
Created by admin on Sat Dec 16 18:24:04 GMT 2023 , Edited by admin on Sat Dec 16 18:24:04 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY